Gene Therapy
Conference Coverage
‘Superior’ CLL regimen cuts chemo in half
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...
News
FDA approves liso-cel as second-line therapy for LBCL
Liso-cel could now become a “new standard of care for patients after failure of first-line therapy,” offering significantly improved outcomes for...
Conference Coverage
Novel gene therapy offers hope for some lymphomas
Novel CAR T-cell product shows promise for second-line treatment of relapsed and refractory lymphoma patients in a pilot study.
Latest News
‘Exciting’ new gene therapy yields promising results
A single dose of CAR-T cell therapy evoked a beneficial response in patients with relapsed or refractory non-Hodgkin lymphoma.
Conference Coverage
‘Very impressive’ data promise new blood cancer option
Early data from MajesTEC-1 phase 1-2 studies showed high response rates in patients with relapsed or refractory disease.
Conference Coverage
'New benchmark' set in phase-3 blood cancer study
Phase 3 SHINE study of older patients with mantle cell lymphoma yields “profound” results with ibrutinib add-on.
Sponsored Supplement
Fundamentals of Gene Therapy: Addressing Gaps in Physician Education
From the Journals
First-line CAR T-cell therapy could help cure some lymphomas
Axi-cel is already approved for some forms of relapsed/refractory lymphoma, and a new phase 2 study hints that it has potential as a frontline...
From the Journals
Gene therapy for hemophilia A: `Truly transformative and liberating’
This first-generation gene therapy offers a new choice for care that could be 'truly transformative and liberating' for eligible men with...
From the Journals
Gene therapy: A ‘one and done’ hemophilia B treatment?
Phase 3 study of a one-time gene therapy shot enabled almost all hemophilia B patients to end full-dose bleeding prophylaxis.
Conference Coverage
New hemophilia treatments: ‘Our cup runneth over’
A range of new options is emerging to treat hemophilia patients.
Conference Coverage
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...